Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,522.38 20.73 0.13%
S&P 500 1,882.73 7.34 0.39%
NASDAQ 4,152.97 26.00 0.63%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

DGAP-PVR: STRATEC Biomedical AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with



DGAP-PVR: STRATEC Biomedical AG: Release according to Article 26, Section 1 of 
the WpHG [the German Securities Trading Act] with the objective of Europe-wide 
distribution

STRATEC Biomedical AG 

16.12.2013 15:40

Dissemination of a Voting Rights Announcement, transmitted by
DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------


Allianz SE, Munich, Germany, notified us on December 12, 2013 pursuant to
section 21 (1) of the German Securities Trading Act (WpHG) as follows:

'We hereby give notice pursuant to section 21 (1) of the German Securities
Trading Act (WpHG) that our voting rights in STRATEC Biomedical AG,
Gewerbestr. 37, 75217 Birkenfeld, Germany, exceeded the threshold of 5% on
December 10, 2013 and amounted to 5.11% of all voting rights in the
company, corresponding to 601,001 of the total 11,770,245 voting rights.

These voting rights are attributed to us pursuant to section 22 (1)
sentence 1 number 1 of the German Securities Trading Act (WpHG) and
pursuant to section 22 (1) sentence 1 number 6 in conjunction with sentence
2 of the German Securities Trading Act (WpHG).

The 600,000 voting rights attributable to us pursuant to section 22 (1)
sentence 1 number 1 of the German Securities Trading Act (WpHG) are held
via the following subsidiaries controlled by us whose share of voting
rights in STRATEC Biomedical AG amounted in each case to 3% or more:
Allianz Europe B.V., Allianz Holding France SAS, Allianz France S.A. and
Allianz I.A.R.D. S.A.

These 600,000 voting rights were also attributable to us pursuant to
section 22 (1) sentence 1 number 6 in conjunction with sentence 2 of the
German Securities Trading Act (WpHG) via a shareholder whose share of
voting rights amounted to 3% or more: Allianz I.A.R.D. S.A.'



Moreover, Allianz SE, Munich, Germany, notified us on December 12, 2013
pursuant to section 25 (1) of the German Securities Trading Act (WpHG) as
follows:

'We also hereby give notice pursuant to section 25 (1) of the German
Securities Trading Act (WpHG) that our share of voting rights in STRATEC
Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld, Germany, exceeded the
threshold of 5% on December 10, 2013 and amounted to 5.18% of all voting
rights in the company, corresponding to 610,001 of the total 11,770,245
voting rights. Due to (financial/other) instruments, the share of voting
rights pursuant to section 25 of the German Securities Trading Act (WpHG)
amounted to 0.08%, corresponding to 9,000 of the total 11,770,245 voting
rights. Of these, 0.08% were held indirectly, corresponding to 9,000 of the
total 11,770,245 voting rights. The share of voting rights pursuant to
sections 21 and 22 of the German Securities Trading Act (WpHG) amounted to
5.11%, corresponding to 601,001 of the total 11,770,245 voting rights.

The chain of controlled companies, which held voting rights pursuant to
section 25 (1) of the German Securities Trading Act (WpHG), was as follows:
Allianz Deutschland AG and Allianz Private Krankenversicherungs-AG.

The financial/other instruments pursuant to section 25 of the German
Securities Trading Act (WpHG) were return claims arising from securities
lending with indefinite maturities.'



Moreover, Allianz SE, Munich, Germany, notified us on December 12, 2013
pursuant to section 21 (1) of the German Securities Trading Act (WpHG) in
conjunction with section 24 (1) of the German Securities Trading Act (WpHG)
as follows:

'1. The share of voting rights held by Allianz Europe B.V., Amsterdam,
Netherlands, in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld,
Germany, exceeded the threshold of 5% on December 10, 2013 and amounted to
5.10% of all voting rights in the company, corresponding to 600,000 of the
total 11,770,245 voting rights. These voting rights are attributed to
Allianz Europe B.V. pursuant to section 22 (1) sentence 1 number 1 of the
German Securities Trading Act (WpHG).

The voting rights attributed to Allianz Europe B.V. were held via the
following companies controlled by Allianz Europe B.V. whose share of the
voting rights in STRATEC Biomedical AG amounted to 3% or more in each case:
Allianz Holding France SAS, Allianz France S.A., and Allianz I.A.R.D. S.A.


2. The share of voting rights held by Allianz Holding France SAS, Paris,
France, in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld,
Germany, exceeded the threshold of 5% on December 10, 2013 and amounted to
5.10% of all voting rights in the company, corresponding to 600,000 of the
total 11,770,245 voting rights. These voting rights are attributed to
Allianz Holding France SAS pursuant to section 22 (1) sentence 1 number 1
of the German Securities Trading Act (WpHG).

The voting rights attributed to Allianz Holding France SAS were held via
the following companies controlled by Allianz Holding France SAS whose
share of the voting rights in STRATEC Biomedical AG amounted to 3% or more
in each case: Allianz France S.A. and Allianz I.A.R.D. S.A.


3. The share of voting rights held by Allianz France S.A., Paris, France,
in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld, Germany,
exceeded the threshold of 5% on December 10, 2013 and amounted to 5.10% of
all voting rights in the company, corresponding to 600,000 of the total
11,770,245 voting rights. These voting rights are attributed to Allianz
France S.A. pursuant to section 22 (1) sentence 1 number 1 of the German
Securities Trading Act (WpHG).

The voting rights attributed to Allianz France S.A. were held via the
following company controlled by Allianz France S.A. whose share of the
voting rights in STRATEC Biomedical AG amounted to 3% or more: Allianz
I.A.R.D. S.A.


4. The share of voting rights held by Allianz I.A.R.D. S.A., Paris, France,
in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld, Germany,
exceeded the threshold of 5% on December 10, 2013 and amounted to 5.10% of
all voting rights in the company, corresponding to 600,000 of the total
11,770,245 voting rights.


5. The share of voting rights held by Allianz Asset Management AG, Munich,
Germany, in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld,
Germany, exceeded the threshold of 5% on December 10, 2013 and amounted to
5.11% of all voting rights in the company, corresponding to 601,001 of the
total 11,770,245 voting rights. These voting rights are attributed pursuant
to section 22 (1) sentence 1 number 6 in conjunction with sentence 2 of the
German Securities Trading Act (WpHG).

Of these, 600,000 voting rights were also attributable to us pursuant to
section 22 (1) sentence 1 number 6 in conjunction with sentence 2 of the
German Securities Trading Act (WpHG) via a shareholder whose share of
voting rights amounted to 3% or more: Allianz I.A.R.D. S.A.


6. The share of voting rights held by Allianz Global Investors GmbH,
Munich, Germany, in STRATEC Biomedical AG, Gewerbestr. 37, 75217
Birkenfeld, Germany, exceeded the threshold of 5% on December 10, 2013 and
amounted to 5.11% of all voting rights in the company, corresponding to
601,001 of the total 11,770,245 voting rights. These voting rights are
attributed pursuant to section 22 (1) sentence 1 number 6 in conjunction
with sentence 2 of the German Securities Trading Act (WpHG).

Of these, 600,000 voting rights were also attributable to us pursuant to
section 22 (1) sentence 1 number 6 in conjunction with sentence 2 of the
German Securities Trading Act (WpHG) via a shareholder whose share of
voting rights amounted to 3% or more: Allianz I.A.R.D. S.A.


7. The share of voting rights held by Allianz Global Investors France S.A.,
Paris, France, in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld,
Germany, exceeded the threshold of 5% on December 10, 2013 and amounted to
5.15% of all voting rights in the company, corresponding to 606,045 of the
total 11,770,245 voting rights. These voting rights are attributed pursuant
to section 22 (1) sentence 1 number 6 of the German Securities Trading Act
(WpHG).

Of these, 600,000 voting rights were also attributable to us pursuant to
section 22 (1) sentence 1 number 6 of the German Securities Trading Act
(WpHG) via a shareholder whose share of voting rights amounted to 3% or
more: Allianz I.A.R.D. S.A.'



16.12.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      STRATEC Biomedical AG
              Gewerbestr. 37
              75217 Birkenfeld
              Germany
Internet:     www.stratec.com
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement